High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma

Overview of attention for article published in Clinical Cancer Research, March 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

twitter: 20 X users

guideline: 1 clinical guideline source

Readers on

mendeley: 69 Mendeley

So far, Altmetric has seen 22 X posts from 20 X users, with an upper bound of 46,717 followers.

High-Specific-Activity- 131 I-MIBG versus 177 Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma - PubMed https://t.co/TR0rsTnQUZ

RT @SCIDirector: SCI member Andrei Iagaru & colleagues discuss and provide expert recommendations on how to select between several FDA-appr…

SCI member Andrei Iagaru & colleagues discuss and provide expert recommendations on how to select between several FDA-approved targeted #radionuclide therapies for metastatic/inoperable #pheochromocytoma and #paraganglioma https://t.co/5RJ0alHNNg @C…

RT @NANETS1: NANETS members @JaydiDelRivero, @thomashopemd, Jonathan Strosberg & Joseph Dillon co-authored: High-specific-activity 131I-MIB…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 18 additional X posts.